[Aromatase inhibitors in the adjuvant therapy of breast cancer]. / Aromataseinhibitoren in der adjuvanten Therapie des Mammakarzinoms.
Gynakol Geburtshilfliche Rundsch
; 45(3): 132-6, 2005 Jun.
Article
em De
| MEDLINE
| ID: mdl-15990437
ABSTRACT
Breast cancer is a hormone-sensitive cancer and in most post-menopausal women hormone receptor positive. The hormone receptor status is a highly valid predictive marker of responsiveness to endocrine therapy. The standard adjuvant therapy in patients with hormone-receptor-positive breast cancer is the selective estrogen receptor modulator tamoxifen. Third-generation aromatase inhibitors are accepted as a treatment option for metastatic breast cancer. However, results from recent studies show also a benefit of this type of drugs for disease-free survival with fewer adverse reactions in the adjuvant therapy. Therefore a new therapeutic field opens for the use of 3rd-generation aromatase inhibitors. This will lead to an expansion of the indication, but the question of modality -- up-front, switch or extended therapy -- remains to be resolved.
Buscar no Google
Coleções:
01-internacional
Base de dados:
MEDLINE
Assunto principal:
Neoplasias da Mama
/
Antineoplásicos Hormonais
/
Inibidores da Aromatase
/
Neoplasias Hormônio-Dependentes
Tipo de estudo:
Prognostic_studies
Limite:
Female
/
Humans
Idioma:
De
Revista:
Gynakol Geburtshilfliche Rundsch
Assunto da revista:
GINECOLOGIA
/
OBSTETRICIA
Ano de publicação:
2005
Tipo de documento:
Article